Jurado-Santa Cruz F, Páez-Agraz F

Language: Spanish
References: 11
Page: 304-311
PDF size: 298.64 Kb.

ABSTRACT

Vulgar psoriasis is an inflammatory cutaneous-systemic disease, chronic and intermittent. Its etiology is not defined, and it has a higher risk of comorbidities which affect the patients’ quality of life. The objectives of this trial were establishing the concordance between Guía de Práctica Clínica (GPC) of the plaque psoriasis pharmacological treatment and the clinical practice of a group of Mexican dermatologists, experts in the psoriasis topical treatment; as well as weighing up the interest and knowledge of quality of life and adherence to treatment. A Delphi questionnaire was applied to 30 experts to explore their therapeutic behavior and attitudes toward the assessment of quality of life and treatment adherence. A meeting was held with a subgroup of 10 dermatologists to analyze the results. A second questionnaire was responded to distinguish the decisions taken for topical treatment in institutional and private practice, as well as other items unexplored in the first questionnaire. After analyzing the questionnaires results, it was clear that the data published in the Guía de Práctica Clínica and the prescriptive attitude of the experts are consistent with respect to the topical treatment for plaque psoriasis. There is also agreement on the attitude about drug prescriptions between the physicians in the private and institutional medical care, although in the private practice it is more common to use vitamin D analogues and corticosteroids and the salicylic acid replaces corticosteroids in the institutions.

REFERENCES

1. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014 Apr 17; 7:119-32.

2. Amaya GM, Barba F, Blancas GF, Gómez FM, Gómez TA, González SR, et al. Consenso Mexicano para el Manejo de Terapia Biológica en Psoriasis. Rev Cent Dermatol Pascua. 2004;13(3):172-84.

3. Gottlieb A, Korman N, Gordon KB, Feldman SR, Lebwohl M, Koo JYM, et al. Guidelines of care for the management of psoriasis and psoriasis arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for the treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-64.

4. Richard MA. Psoriasis: Practical pre-therapeutic assessment. Ann Dermatol Venereol. 2011;138(12):813-20.

5. Centro Nacional de Excelencia Tecnológica en Salud [CENETEC]. Tratamiento farmacológico para pacientes adultos con psoriasis en placas. México: Secretaría de Salud; 2013. Disponible en http://www.cenetec. salud.gob.mx/descargas/gpc/CatalogoMaestro/ IMSS-696-FARMACOLOGICO_PSORIASIS_EN_ PLACAS/IMSS-696-13-GER-TX_FX_PSORIASIS_ EN_PLACAS.pdf

6. Juliá M, Moreno R. Tratamiento tópico de la psoriasis: actualización. Med Cutan Iber Lat Am. 2005;33:147-57.

7. Diette KM, Momtaz K, Stern RS, Arndt KA, Parrish JA. Role of ultraviolet A in phototherapy for psoriasis. J Am Acad Dermatol. 1984 Sep; 11(3):441-7.

8. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). S3-Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012 Mar; 10 Suppl 2:S1-95.

9. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriasis arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643-59.

10. Barankin B, DeKoven J. Psychosocial effect of common skin Diseases. Can Fam Physician. Le Médecin de famille canadien. 2002;48:712-6.

11. Young WL, Park EJ, Kwon IH, Kim KH, Kim KK. Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life. Ann Dermatol. 2010;22(4):389:346.